FibroTouch联合超声和CT检查诊断高原地区非酒精性脂肪性肝病临床应用研究*

doi:10.3969/j.issn.1672-5069.2020.06.015

摘要/Abstract

摘要： 目的评价FibroTouch(FT)联合超声和CT检查诊断青海高原地区非酒精性脂肪性肝病(NAFLD)患者的临床应用价值。方法 2018年8月～2019年5月青海省人民医院消化科住院的非酒精性脂肪性肝病患者343例,所有人员同时接受FT、腹部超声和腹部CT检查,分析任意检查对NAFLD的检出率,并分析FT相对于腹部超声和CT诊断NAFLD的灵敏度、特异度和受试者工作特征曲线下面积(AUROC),以Kappa值评价FT与这两种方法诊断的一致性,分析FT单独和联合这两种方法诊断NAFLD的检出率。结果 FT诊断本组人群NAFLD的检出率为63.9%,腹部超声诊断检出率为40.2%,腹部CT检出率为26.2%;相对于腹部超声诊断NAFLD,FT检查的灵敏度为82.6%,特异度为48.8%,AUROC为0.657(95%CI:0.610～0.704);相对于腹部CT诊断NAFLD,FT检查诊断的灵敏度为88.9%,特异度为45.1%,AUROC为0.670(95%CI:0.624～0.715);FT检查与腹部超声检查诊断NAFLD的总体一致性为62.4%,Kappa系数为0.29,说明两者诊断的一致性较差;FT检查与腹部CT检查诊断的总体一致性为56.6%,Kappa系数为0.23,两者诊断的一致性也较差;三者联合检查均诊断为NAFLD患者247例,其中FT检查、腹部超声和腹部CT检查的单独检出率分别为88.7%、55.9%和36.4%,联合FibroTouch和腹部超声诊断或联合FT和腹部CT诊断将检出率分别提高到98.4%和92.7%。结论使用FT检查、腹部超声和腹部CT检查诊断NAFLD的一致性较差,联合FT和腹部超声诊断、联合FT和腹部CT诊断能进一步提高高原地区人群NAFLD的检出率。

关键词: 非酒精性脂肪性肝病, FibroTouch, 高原地区, 诊断

Abstract: Objective The aim of this study was to evaluate the clinical application of FibroTouch (FT) in combination with abdominal color ultrasound and computed tomography (CT) in diagnosis of individuals with nonalcoholic fatty liver disease in plateau regions. Methods A total of 343 persons with nonalcoholic fatty liver disease (NAFLD) were enrolled in the Department of Gastroenterology in the Qinghai Provincial People's Hospital between August 2018 and May 2019. The NAFLD was diagnosed by the examination of FT, abdominal color ultrasound, or CT. The diagnostic sensitivity, consistency, and diagnosis rate of FT relative to ultrasound or CT examination were analyzed by AUROC and Kappa value. Results The diagnosed rate of NAFLD by FT, ultrasound and CT examination were 63.9%, 40.2% and 26.2%, respectively, in our series; the diagnosis sensitivity and specificity of FT relative to ultrasoundex amination were 82.6% and 48.8% (AUROC=0.657, 95% CI: 0.610-0.704), and those relative to CT examination were 88.9% and 45.1% (AUROC=0.670, 95% CI: 0.624-0.715); the diagnostic results of FT had a lower consistency with both ultrasound or CT diagnosis by 62.4% (Kappa coefficient = 0.29) and 56.6% (Kappa coefficient = 0.23) ,respectively; the diagnostic rates of FT, ultrasound and CT examination were 88.7%, 55.9% and 36.3%, respectively; the diagnostic rates were raised to 98.4% and 92.7 when the FT combined with ultrasound examination or CT examination, respectively. Conclusions There is a lower consistency between FT and ultrasound or CT examination in diagnosis of NAFLD, while the diagnostic rate of NAFLD could be improved by FT combined with ultrasound or CT examination in persons in plateau regions.

Key words: Nonalcoholic fatty liver diseases, FibroTouch, Plateau regions, Diagonsis

李萍英, 李娟, 谢守珍, 杨永耿, 陆伦根. FibroTouch联合超声和CT检查诊断高原地区非酒精性脂肪性肝病临床应用研究^*[J]. 实用肝脏病杂志, 2020, 23(6): 817-820.

Li Pingying, Li Juan, Xie Shouzhen, et al. Clinical application of FibroTouchand abdominal color ultrasound and computed tomography in diagnosis of individuals with nonalcoholic fatty liver disease in plateau regions[J]. Journal of Practical Hepatology, 2020, 23(6): 817-820.

参考文献

[1] Li ZZ, Xue J, Chen P,et al. Prevalence of nonalcoholic fatty liver disease in mainland of China: A meta-analysis of published studies. J GastroenterolHepatol, 2014, 29(1):Z42-251.
[2] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic Fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, 64(1):73-84.
[3] Cengiz M, Sentürk S, Cetin B, et al. Sonographic assessment of fatty liver: intraobserver and interobserver variability. Int J Clin Exp Med, 2014, 7(12):5453.
[4] Wong LH. Prediction of fibrosis progression in chronic viral hepatitis. Clin Mol Hepatol, 2014, 20(3): 228-236.
[5] Ou XJ, Wang XM, Wu XN, et al. Comparison of FibroTouch and FibroScan for the assessment of fibrosis in chronic hepatitis B patients. Chin J Hepatol, 2015, 23(2): 103-106.
[6] Deng H, Wang C, Lai J, et al. Noninvasive diagnosis of hepatic steatosis using fat attenuation parameter measured by FibroTouch and a new algorithm in CHB patients. Hepat Mon,2016, 16(9):e40263.
[7] Lei J, Ji X, Hong J, et al. Prediction of posthepatectomy liver failure using transient elastography in patients with hepatitis B related hepatocellular carcinoma. BMC Gastroenterol, 2017, 17: 171.
[8] Xu Y, Liu Y, Cao Z, et al. Comparison of FibroTouch and FibroScan for staging fibrosis in chronic liver disease: single-center prospective study. Dig Liver Dis, 2019, 51(9):1323-1329.
[9] Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis. Hepatology, 2019, 70:1119-1133.
[10] Cai W, Song J, Zhang B, et al. The prevalence of nonalcoholic fatty liver disease and relationship with serum uric acid level in Uyghur population. Sci World J, 2014, 23(6):393628.
[11] 管红雨,蔡晓波,陆伦根.缺氧对非酒精性脂肪性肝病发病的影响.实用肝脏病杂志,2016, 19(2):237-240.
[12] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会. 非酒精性脂肪性肝病防治指南(2018 年版). 实用肝脏病杂志,2018,21(2):177-186.
[13] 李静波,刘姝,温博,等.FibroTouch与超声、CT对NAFLD的诊断价值比较.临床肝胆病杂志,2016,34(3): 459-462.
[14] 温博,王炳元,李静波,等.Fibrotouch与超声诊断NAFLD一致性分析.中国肝脏病杂志(电子版),2016,8(2):19-23.
[15] Stern C, Castera L. Non-invasive diagnosis of hepatic steatosis. Hepatol Int, 2017,11: 70-78.
[16] Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol,2013, 10:666-675.
[17] Marshall RH, Eissa M, Bluth EI, et al. Hepatorenal index as an accurate, simple, and effective tool in screening for steatosis. Am J Roentgenol, 2012, 199(5): 997-1002.
[18] Shen L1, Li JQ, Zeng MD,et al. Correlation between ultrasonographic and pathologic diagnosis of liver fibrosis due to chronic virus hepatitis. World J Gastroenterol, 2006, 12(8): 1292-1295.
[19] Tada T,Kumada T,Toyoda H,et al. Progression of liver fibrosis is associated with non-liver-related mortality in patients with nonalcoholic fatty liver disease. Hepatol Commun,2017,1(9):899-910.
[20] Andrade P, Rodrigues S, Rodrigues-Pinto E, et al. Diagnostic accuracy of controlled attenuation parameter for detecting hepatic steatosis in patients with chronic liver disease. GE Port J Gastroenterol, 2017, 24(4):161-168.
[21] Kaya E,Demir D,Alahdab YO,et al. Prevalence of hepaticsteatosis in apparently healthy medical students:a transient elastography study on the basis of a controlled attenuation parameter. Eur J Gastroenterol Hepatol, 2016, 28(11): 1264-1267.

FibroTouch联合超声和CT检查诊断高原地区非酒精性脂肪性肝病临床应用研究^*

Clinical application of FibroTouchand abdominal color ultrasound and computed tomography in diagnosis of individuals with nonalcoholic fatty liver disease in plateau regions

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	荣爱梅, 张超, 吴慧丽. 西罗莫司对高脂饮食诱导的NAFLD大鼠外周血Treg/Th17细胞的影响[J]. 实用肝脏病杂志, 2021, 24(1): 10-13.
[2]	吴冬秋, 崔丽华, 熊峰, 邬政宏. 血清IL-34联合超声弹性成像诊断慢性乙型肝炎患者肝纤维化的效能分析[J]. 实用肝脏病杂志, 2021, 24(1): 23-26.
[3]	陈光榆, 王鸿, 王耀晟, 张熙, 张伟, 曾静, 沈峰, 胡颖, 范建高. 非酒精性脂肪性肝病患者血红蛋白水平变化及其临床意义[J]. 实用肝脏病杂志, 2021, 24(1): 39-42.
[4]	夏淑晶, 张莉莉, 张秀梅, 赵根宝, 周松伟, 罗欲承, 陈红芹, 王子华, 成凤干, 范建高. 非酒精性脂肪性肝病患者血清SDC4变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(1): 43-46.
[5]	魏秀琴, 闫晓霞, 石国荣, 赵宏伟, 李基寿. 阿托伐他汀联合硫普罗宁治疗非酒精性脂肪性肝病患者疗效初步研究[J]. 实用肝脏病杂志, 2021, 24(1): 47-50.
[6]	梁小丽, 邝继孙, 刘秋莉, 符弟. 非诺贝特联合热量限制饮食治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 51-54.
[7]	赵晓春, 钟庆, 刘书宏, 梁尘格, 郭熙清, 温林. 非酒精性脂肪性肝病并发2型糖尿病患者血尿酸水平变化及其临床意义[J]. 实用肝脏病杂志, 2021, 24(1): 55-58.
[8]	李钊, 黄赞松, 李繁. 非诺贝特联合双环醇治疗非酒精性脂肪性肝病患者肝组织PPARγ₂mRNA水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 59-62.
[9]	陈金玉, 郭晓霞, 钟晓妮. 二甲双胍联合双歧杆菌三联活菌胶囊治疗非酒精性脂肪性肝病患者疗效及血清IRS1、IRS2和GLUT4的变化[J]. 实用肝脏病杂志, 2021, 24(1): 63-66.
[10]	张昕, 郭悦, 杨军. 瞬时弹性成像测定肝脾硬度值评估乙型肝炎肝硬化患者食管静脉曲张初步研究[J]. 实用肝脏病杂志, 2021, 24(1): 95-98.
[11]	韩冬, 陆洋, 柏根基, 史昭菲. 超声声速匹配联合磁共振弥散加权成像技术评估慢性乙型肝炎患者肝纤维化程度价值分析^*[J]. 实用肝脏病杂志, 2020, 23(6): 789-792.
[12]	柳迪, 董鑫, 杨建军, 吴云英, 张龙方, 刘妍. 瞬时弹性成像联合门静脉血流动力学指标诊断慢性乙型肝炎患者肝纤维化意义探讨^*[J]. 实用肝脏病杂志, 2020, 23(6): 797-800.
[13]	崔璐瑶, 苑喜微, 刘领弟, 张莹, 赵文, 赵丹丹, 杨杨, 南月敏. 血浆GP73联合肝脏硬度检测诊断乙型和丙型肝炎患者肝纤维化临床价值分析^*[J]. 实用肝脏病杂志, 2020, 23(6): 809-812.
[14]	孙浩, 朱桂娟, 陈小宇. 多层螺旋CT测定全肝体积/脾脏体积比对诊断肝硬化的价值研究[J]. 实用肝脏病杂志, 2020, 23(6): 837-840.
[15]	宋丽俊, 鲁雪红, 薛志伟, 张梅, 王伟. CT血管三维重建鉴别布加综合征与乙型肝炎肝硬化价值分析^*[J]. 实用肝脏病杂志, 2020, 23(6): 865-868.